ex-US Commercialization
Most Rare Disease Therapies Never Reach 70% of the World. We Fix That.
Biomedica helps biopharma innovators commercialize rare and specialty therapies across 30+ ex-US regions through local infrastructure, physician networks, regulatory execution, and end-to-end region-specific commercialization.
Trusted by innovators including
The Problem
Expanding Beyond Core Territories Is Hard
Internal Overload
Your team is already focused on core launch priorities. The challenge isn't ambition. It's execution capacity. Expanding beyond core territories requires more than ambition, it requires local execution expertise.
Fragmented Execution
Multiple distributors. Misaligned incentives. Little visibility.
No Local Relationships
Physicians, KOLs, payers and patient organizations remain difficult to activate.
That's where Biomedica comes in.
Why Biomedica
Why Leading Biopharma Teams Choose Biomedica
One Partner, Multiple Regions
One aligned partner instead of fragmented execution across multiple territories. Built for complex, underserved, and hard-to-operate territories.
Local execution where global teams struggle
We operate in regions many global teams find difficult to navigate. Built for complex, underserved, and hard-to-operate territories.
Local Teams. Real Relationships.
Boots on the ground across 30+ regions with established local infrastructure.
From Regulatory to First Sales
We execute both registered and non-registered pathways end-to-end. Operationally aligned to support region-specific pathways.
Rare Disease Expertise
Focused on orphan, specialty, and low-volume/high-value therapies. We align local physicians, KOLs, payers, and patient organizations to help therapies reach the right patients.
Faster Commercialization
Selected launches achieved first sales within 6–8 months after agreement signature.
The Model
We Don't Just Open Territories. We Build Access.
Traditional Approach
Fragmented execution
- Multiple disconnected regional partners
- Limited visibility and coordination
- Slow execution across territories
- Limited physician activation
- Operational complexity
The Biomedica Model
One aligned structure
- One aligned commercialization partner
- Local operational teams already in place
- Regulatory + supply chain + physician enablement
- Physician enablement supported by medical expertise
- End-to-end region-specific execution
- Faster patient access
Our Footprint
30+ Regions. One Contract. One Partner.
ex-US Regions
- Broad European regional coverage
- CIS including difficult-to-operate territories
- Turkey & Israel
- Emerging and underserved regions
- Complex and hard-to-operate territories
- Local teams already in place
Helping innovative therapies reach patients in regions that are often difficult to navigate and scale.
We're meeting innovative biotech companies seeking
- ex-US commercialization
- rare disease expansion
- orphan drug partnerships
- distribution or licensing opportunities
Social Proof
Real Conversations. Real Partnerships.
Press Release
Santhera × Biomedica
Distribution agreement for orphan therapy commercialization across ex-US regions.
Orphan launches since 2019
From agreement to first sales
Ready when you are
Ready to Explore ex-US Growth?
Whether you are preparing for FDA approval, seeking commercialization support, or evaluating expansion opportunities beyond core territories, Biomedica can help.